Comprehensive genomic characterization of squamous cell lung cancers
Open accessThe DOI matches its Crossref record; 45 of the 46 references it cites were found in a registry or an index, and 1 are not checked yet.
Abstract
Lung squamous cell carcinoma is a common type of lung cancer, causing approximately 400,000 deaths per year worldwide. Genomic alterations in squamous cell lung cancers have not been comprehensively characterized, and no molecularly targeted agents have been specifically developed for its treatment. As part of The Cancer Genome Atlas, here we profile 178 lung squamous cell carcinomas to provide a comprehensive landscape of genomic and epigenomic alterations. We show that the tumour type is characterized by complex genomic alterations, with a mean of 360 exonic mutations, 165 genomic rearrangements, and 323 segments of copy number alteration per tumour. We find statistically recurrent mutations in 11 genes, including mutation of TP53 in nearly all specimens. Previously unreported loss-of-function mutations are seen in the HLA-A class I major histocompatibility gene. Significantly altered pathways included NFE2L2 and KEAP1 in 34%, squamous differentiation genes in 44%, phosphatidylinositol-3-OH kinase pathway genes in 47%, and CDKN2A and RB1 in 72% of tumours. We identified a potential therapeutic target in most tumours, offering new avenues of investigation for the treatment of squamous cell lung cancers. Comprehensive analyses of 178 lung squamous cell carcinomas by The Cancer Genome Atlas project show that the tumour type is characterized by complex genomic alterations, with statistically recurrent mutations in 11 genes, including TP53 in nearly all samples; a potential therapeutic target is identified in most of the samples studied. The Cancer Genome Atlas consortium has analysed 178 lung squamous cell carcinomas, a common type of lung cancer for which comprehensive genomic analyses have not previously been available. The researchers report that this tumour type is characterized by complex genomic alterations, with recurrent mutations in 18 genes, including TP53 in nearly all samples. They also report frequent mutations in squamous differentiation genes. Collectively, these analyses identify potential therapeutic targets worthy of further investigation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Despite many additional doublings in culture, this point mutational frequency (2.16 per Mb) is on the lower end of frequencies observed across different cancer genomes22.”
From The haplotype-resolved genome and epigenome of the aneuploid HeLa cancer cell line (2013) · cites this paper as [22]
Experimental — accuracy not yet measuredIn the citing paper
“Genomic characterization of squamous cell lung cancers showed significant alterations in the Nrf2 pathway in 34% of all tumour specimens examined [175].”
From Nrf2 and Oxidative Stress: A General Overview of Mechanisms and Implications in Human Disease (2022) · cites this paper as [175]
In the citing paper
“Combined PI3K and CDK4/6 inhibition may also be of substantial interest in squamous cell NSCLC and head and neck cancer, where amplification of both CCND1 and PIK3CA are common events (117, 118), as well as in pancreatic cancer, where genetically engineered mouse models have suggested the importance of the PI3K pathway downstream from activated KRAS (119).”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [118]
In the citing paper
“The TP53 mutation rate exceeds 70% in certain subtypes of cancers, including squamous esophageal cancer, small-cell lung cancer, squamous cell lung cancer, and complex karyotype acute myeloid leukemia (AML), and is lower in partial tumors such as lymphoma, melanoma, and overall AML.8–11”
From p53: from understanding its structure to advances in therapeutic targeting (2026) · cites this paper as [10]
In the citing paper
“The TP53 mutation rate exceeds 70% in certain subtypes of cancers, including squamous esophageal cancer, small-cell lung cancer, squamous cell lung cancer, and complex karyotype acute myeloid leukemia (AML), and is lower in partial tumors such as lymphoma, melanoma, and overall AML.8–11”
From p53: from understanding its structure to advances in therapeutic targeting (2026) · cites this paper as [10]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Self-citationIntegrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,925
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
Soda, M., Choi, Y. L., Enomoto, M., Takada, S., Yamashita, Y., Ishikawa, S., Fujiwara, S.-I., Watanabe, H., Kurashina, K., Hatanaka, H., et al. (2007) · Nature · doi:10.1038/nature05945 · Cited by 5,439 · cited 1×
“2); (2) confirmation of the altered allele in RNA sequencing; and (3) the mutation assessor score(40).”
BackgroundPao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338
The landscape of somatic copy-number alteration across human cancers
Beroukhim, R., Mermel, C. H., Porter, D., Wei, G., Raychaudhuri, S., Donovan, J., Barretina, J., Boehm, J. S., Dobson, J., Urashima, M., et al. (2010) · Nature · doi:10.1038/nature08822 · Cited by 4,017
Self-citationMermel, C. H., Schumacher, S. E., Hill, B., Meyerson, M. L., Beroukhim, R., & Getz, G. (2011) · Genome Biology · doi:10.1186/gb-2011-12-4-r41 · Cited by 3,550
Brahmer, J. R., Drake, C. G., Wollner, I., Powderly, J. D., Picus, J., Sharfman, W. H., Stankevich, E., Pons, A., Salay, T. M., McMiller, T. L., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.7609 · Cited by 2,961
Cited by
Items 401–500 of 1,021
From human genome to cancer genome: The first decade
Wheeler, D. A., & Wang, L. (2013) · Genome Research · doi:10.1101/gr.157602.113 · Cited by 175
Detecting repeated cancer evolution from multi-region tumor sequencing data
Caravagna, G., Giarratano, Y., Ramazzotti, D., Tomlinson, I., Graham, T. A., Sanguinetti, G., & Sottoriva, A. (2018) · Nature Methods · doi:10.1038/s41592-018-0108-x · Cited by 173
Nanotechnology in the diagnosis and treatment of lung cancer
Cryer, A. M., & Thorley, A. J. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.02.010 · Cited by 172
Kim, H. S., Mendiratta, S., Kim, J., Pecot, C. V., Larsen, J. E., Zubovych, I., Seo, B. Y., Kim, J., Eskiocak, B., Chung, H., et al. (2013) · Cell · doi:10.1016/j.cell.2013.09.041 · Cited by 172
Monitoring Keap1–Nrf2 interactions in single live cells
Baird, L., Swift, S., Llères, D., & Dinkova-Kostova, A. T. (2014) · Biotechnology Advances · doi:10.1016/j.biotechadv.2014.03.004 · Cited by 167
MCL-1 inhibitors, fast-lane development of a new class of anti-cancer agents
Bolomsky, A., Vogler, M., Köse, M. C., Heckman, C. A., Ehx, G., Ludwig, H., & Caers, J. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-01007-9 · Cited by 168
Detecting somatic point mutations in cancer genome sequencing data: a comparison of mutation callers
Wang, Q., Jia, P., Li, F., Chen, H., Ji, H., Hucks, D., Dahlman, K. B., Pao, W., & Zhao, Z. (2013) · Genome Medicine · doi:10.1186/gm495 · Cited by 170
Owada-Ozaki, Y., Muto, S., Takagi, H., Inoue, T., Watanabe, Y., Fukuhara, M., Yamaura, T., Okabe, N., Matsumura, Y., Hasegawa, T., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.04.003 · Cited by 170
Wang, K., Ji, W., Yu, Y., Li, Z., Niu, X., Xia, W., & Lu, S. (2018) · Oncogene · doi:10.1038/s41388-018-0311-3 · Cited by 169
Remon, J., Passiglia, F., Ahn, M.-J., Barlesi, F., Forde, P. M., Garon, E. B., Gettinger, S., Goldberg, S. B., Herbst, R. S., Horn, L., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.03.006 · Cited by 169
Immune Escape Mechanisms in Non Small Cell Lung Cancer
Anichini, A., Perotti, V. E., Sgambelluri, F., & Mortarini, R. (2020) · Cancers · doi:10.3390/cancers12123605 · Cited by 169
Regulation of the Keap1–Nrf2 pathway by p62/SQSTM1
Katsuragi, Y., Ichimura, Y., & Komatsu, M. (2016) · Current Opinion in Toxicology · doi:10.1016/j.cotox.2016.09.005 · Cited by 168
Squamous Cell Lung Cancer: From Tumor Genomics to Cancer Therapeutics
Gandara, D. R., Hammerman, P. S., Sos, M. L., Lara, P. N., & Hirsch, F. R. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3039 · Cited by 168
Inhibitor-Sensitive FGFR2 and FGFR3 Mutations in Lung Squamous Cell Carcinoma
Liao, R. G., Jung, J., Tchaicha, J., Wilkerson, M. D., Sivachenko, A., Beauchamp, E. M., Liu, Q., Pugh, T. J., Pedamallu, C. S., Hayes, D. N., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3950 · Cited by 167
BRAF in non-small cell lung cancer (NSCLC): Pickaxing another brick in the wall
Leonetti, A., Facchinetti, F., Rossi, G., Minari, R., Conti, A., Friboulet, L., Tiseo, M., & Planchard, D. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.04.006 · Cited by 168
NRF2 Activation Promotes Aggressive Lung Cancer and Associates with Poor Clinical Outcomes
Singh, A., Daemen, A., Nickles, D., Jeon, S.-M., Foreman, O., Sudini, K., Gnad, F., Lajoie, S., Gour, N., Mitzner, W., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1985 · Cited by 167
Targeting NRF2 and Its Downstream Processes: Opportunities and Challenges
Torrente, L., & DeNicola, G. M. (2022) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-052220-104025 · Cited by 163
Classification of lung cancer using ensemble-based feature selection and machine learning methods
Cai, Z., Xu, D., Zhang, Q., Zhang, J., Ngai, S.-M., & Shao, J. (2014) · Molecular BioSystems · doi:10.1039/c4mb00659c · Cited by 167
Frank, R., Scheffler, M., Merkelbach-Bruse, S., Ihle, M. A., Kron, A., Rauer, M., Ueckeroth, F., König, K., Michels, S., Fischer, R., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3416 · Cited by 167
Babur, Ö., Gönen, M., Aksoy, B. A., Schultz, N., Ciriello, G., Sander, C., & Demir, E. (2015) · Genome Biology · doi:10.1186/s13059-015-0612-6 · Cited by 166
Large-scale profiling of microRNAs for The Cancer Genome Atlas
Chu, A., Robertson, G., Brooks, D., Mungall, A. J., Birol, I., Coope, R., Ma, Y., Jones, S., & Marra, M. A. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkv808 · Cited by 165
Binkley, M. S., Jeon, Y.-J., Nesselbush, M., Moding, E. J., Nabet, B. Y., Almanza, D., Kunder, C., Stehr, H., Yoo, C. H., Rhee, S., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0282 · Cited by 163
Boolean Network Model for Cancer Pathways: Predicting Carcinogenesis and Targeted Therapy Outcomes
Fumiã, H. F., & Martins, M. L. (2013) · PLoS ONE · doi:10.1371/journal.pone.0069008 · Cited by 164
Comparison of somatic mutation calling methods in amplicon and whole exome sequence data
Xu, H., DiCarlo, J., Satya, R. V., Peng, Q., & Wang, Y. (2014) · BMC Genomics · doi:10.1186/1471-2164-15-244 · Cited by 164
The NRF2, Thioredoxin, and Glutathione System in Tumorigenesis and Anticancer Therapies
Jaganjac, M., Milkovic, L., Sunjic, S. B., & Zarkovic, N. (2020) · Antioxidants · doi:10.3390/antiox9111151 · Cited by 162
Damelin, M., Bankovich, A., Bernstein, J., Lucas, J., Chen, L., Williams, S., Park, A., Aguilar, J., Ernstoff, E., Charati, M., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aag2611 · Cited by 163
Vansteenkiste, J. F., Canon, J.-L., De Braud, F., Grossi, F., De Pas, T., Gray, J. E., Su, W.-C., Felip, E., Yoshioka, H., Gridelli, C., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000607 · Cited by 162
Challenges in molecular testing in non-small-cell lung cancer patients with advanced disease
Hiley, C. T., Le Quesne, J., Santis, G., Sharpe, R., de Castro, D. G., Middleton, G., & Swanton, C. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31340-x · Cited by 163
Fini, M. E., Schwartz, S. G., Gao, X., Jeong, S., Patel, N., Itakura, T., Price, M. O., Price, F. W., Varma, R., & Stamer, W. D. (2017) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2016.09.003 · Cited by 163
MAPK pathway activity plays a key role in PD‐L1 expression of lung adenocarcinoma cells
Stutvoet, T. S., Kol, A., de Vries, E. G., de Bruyn, M., Fehrmann, R. S., Terwisscha van Scheltinga, A. G., & de Jong, S. (2019) · The Journal of Pathology · doi:10.1002/path.5280 · Cited by 162
The cancer COMPASS: navigating the functions of MLL complexes in cancer
Ford, D. J., & Dingwall, A. K. (2015) · Cancer Genetics · doi:10.1016/j.cancergen.2015.01.005 · Cited by 162
Danilova, L., Wang, H., Sunshine, J., Kaunitz, G. J., Cottrell, T. R., Xu, H., Esandrio, J., Anders, R. A., Cope, L., Pardoll, D. M., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1607836113 · Cited by 161
A step-by-step microRNA guide to cancer development and metastasis
Markopoulos, G. S., Roupakia, E., Tokamani, M., Chavdoula, E., Hatziapostolou, M., Polytarchou, C., Marcu, K. B., Papavassiliou, A. G., Sandaltzopoulos, R., & Kolettas, E. (2017) · Cellular Oncology · doi:10.1007/s13402-017-0341-9 · Cited by 161
The mutational landscape of phosphorylation signaling in cancer
Reimand, J., Wagih, O., & Bader, G. D. (2013) · Scientific Reports · doi:10.1038/srep02651 · Cited by 162
Molecular histology of lung cancer: From targets to treatments
Wood, S. L., Pernemalm, M., Crosbie, P. A., & Whetton, A. D. (2015) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2015.02.008 · Cited by 161
Harnessing the potential of epigenetic therapy to target solid tumors
Ahuja, N., Easwaran, H., & Baylin, S. B. (2014) · Journal of Clinical Investigation · doi:10.1172/jci69736 · Cited by 159
Lung cancer chemoprevention: current status and future prospects
Keith, R. L., & Miller, Y. E. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.64 · Cited by 159
Faruki, H., Mayhew, G. M., Serody, J. S., Hayes, D. N., Perou, C. M., & Lai-Goldman, M. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.03.010 · Cited by 159
Molecular biomarkers for lung adenocarcinoma
Calvayrac, O., Pradines, A., Pons, E., Mazières, J., & Guibert, N. (2017) · European Respiratory Journal · doi:10.1183/13993003.01734-2016 · Cited by 158
ARID1A loss in cancer: Towards a mechanistic understanding
Mathur, R. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.05.001 · Cited by 159
M3C: Monte Carlo reference-based consensus clustering
John, C. R., Watson, D., Russ, D., Goldmann, K., Ehrenstein, M., Pitzalis, C., Lewis, M., & Barnes, M. (2020) · Scientific Reports · doi:10.1038/s41598-020-58766-1 · Cited by 158
Elevated NSD3 histone methylation activity drives squamous cell lung cancer
Yuan, G., Flores, N. M., Hausmann, S., Lofgren, S., Kharchenko, V., Angulo‐Ibáñez, M., Sengupta, D., Lu, X., Czaban, I., Azhibek, D. M., et al. (2021) · Nature · doi:10.1038/s41586-020-03170-y · Cited by 173
Yu, K., Chen, B., Aran, D., Charalel, J., Yau, C., Wolf, D. M., van ‘t Veer, L. J., Butte, A. J., Goldstein, T., & Sirota, M. (2019) · Nature Communications · doi:10.1038/s41467-019-11415-2 · Cited by 156
Tracking Cancer Evolution through the Disease Course
Bailey, C., Black, J. R. M., Reading, J. L., Litchfield, K., Turajlic, S., McGranahan, N., Jamal-Hanjani, M., & Swanton, C. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1559 · Cited by 158
Role of the Keap1–Nrf2 Pathway in Cancer
(2014) · Advances in Cancer Research · doi:10.1016/b978-0-12-420117-0.00008-6 · Cited by 158
Characterization of the Usage of the Serine Metabolic Network in Human Cancer
Mehrmohamadi, M., Liu, X., Shestov, A. A., & Locasale, J. W. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.10.026 · Cited by 157
Chitsazzadeh, V., Coarfa, C., Drummond, J. A., Nguyen, T., Joseph, A., Chilukuri, S., Charpiot, E., Adelmann, C. H., Ching, G., Nguyen, T. N., et al. (2016) · Nature Communications · doi:10.1038/ncomms12601 · Cited by 156
Dhanasekaran, S. M., Alejandro Balbin, O., Chen, G., Nadal, E., Kalyana-Sundaram, S., Pan, J., Veeneman, B., Cao, X., Malik, R., Vats, P., et al. (2014) · Nature Communications · doi:10.1038/ncomms6893 · Cited by 155
Cancer Pharmacogenomics: Early Promise, But Concerted Effort Needed
McLeod, H. L. (2013) · Science · doi:10.1126/science.1234139 · Cited by 155
Refining the role for adult stem cells as cancer cells of origin
White, A. C., & Lowry, W. E. (2015) · Trends in Cell Biology · doi:10.1016/j.tcb.2014.08.008 · Cited by 156
McNerney, M. E., Brown, C. D., Wang, X., Bartom, E. T., Karmakar, S., Bandlamudi, C., Yu, S., Ko, J., Sandall, B. P., Stricker, T. P., et al. (2012) · Blood · doi:10.1182/blood-2012-04-426965 · Cited by 175
Gene amplification of the histone methyltransferase SETDB1 contributes to human lung tumorigenesis
Rodríguez‐Paredes, M., de Paz, A. M., Simó‐Riudalbas, L., Sayols, S., Moutinho, C., Morán, S., Villanueva, A., Vázquez-Cedeira, M., Lazo, P. A., Carneiro, F., et al. (2013) · Oncogene · doi:10.1038/onc.2013.239 · Cited by 170
Update on Immunohistochemistry for the Diagnosis of Lung Cancer
Inamura, K. (2018) · Cancers · doi:10.3390/cancers10030072 · Cited by 183
Gallo, L. H., Nelson, K. N., Meyer, A. N., & Donoghue, D. J. (2015) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2015.03.003 · Cited by 166
Zhao, Q., Shi, X., Xie, Y., Huang, J., Shia, B., & Ma, S. (2015) · Briefings in Bioinformatics · doi:10.1093/bib/bbu003 · Cited by 154
An Immunogram for the Cancer-Immunity Cycle: Towards Personalized Immunotherapy of Lung Cancer
Karasaki, T., Nagayama, K., Kuwano, H., Nitadori, J., Sato, M., Anraku, M., Hosoi, A., Matsushita, H., Morishita, Y., Kashiwabara, K., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.01.005 · Cited by 167
Patient Similarity Networks for Precision Medicine
Pai, S., & Bader, G. D. (2018) · Journal of Molecular Biology · doi:10.1016/j.jmb.2018.05.037 · Cited by 154
Wynes, M. W., Hinz, T. K., Gao, D., Martini, M., Marek, L. A., Ware, K. E., Edwards, M. G., Böhm, D., Perner, S., Helfrich, B. A., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3060 · Cited by 165
Anti-cancer peptide-based therapeutic strategies in solid tumors
Karami Fath, M., Babakhaniyan, K., Zokaei, M., Yaghoubian, A., Akbari, S., Khorsandi, M., Soofi, A., Nabi-Afjadi, M., Zalpoor, H., Jalalifar, F., et al. (2022) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-022-00332-w · Cited by 152
Mackenzie, R., Kommoss, S., Winterhoff, B. J. N., Kipp, B. R., García, J. J., Voss, J. S., Halling, K. C., Karnezis, A. N., Senz, J., Yang, W., et al. (2015) · BMC Cancer · doi:10.1186/s12885-015-1421-8 · Cited by 172
Vucic, E. A., Chari, R., Thu, K. L., Wilson, I. M., Cotton, A. M., Kennett, J. Y., Zhang, M., Lonergan, K. M., Steiling, K. A., Brown, C. J., et al. (2013) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2013-0304oc · Cited by 169
LeBoeuf, S. E., Wu, W. L., Karakousi, T. R., Karadal, B., Jackson, S. R., Davidson, S. M., Wong, K.-K., Koralov, S. B., Sayin, V. I., & Papagiannakopoulos, T. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2019.11.012 · Cited by 150
The Cancer Cell Map Initiative: Defining the Hallmark Networks of Cancer
Krogan, N. J., Lippman, S., Agard, D. A., Ashworth, A., & Ideker, T. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.05.008 · Cited by 149
Identification of recurrent regulated alternative splicing events across human solid tumors
Danan-Gotthold, M., Golan‐Gerstl, R., Eisenberg, E., Meir, K., Karni, R., & Levanon, E. Y. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv210 · Cited by 165
Hayes, D. N., Waes, C. V., & Seiwert, T. Y. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.1086 · Cited by 166
Goodwin, J., Neugent, M. L., Lee, S. Y., Choe, J. H., Choi, H., Jenkins, D. M. R., Ruthenborg, R. J., Robinson, M. W., Jeong, J. Y., Wake, M., et al. (2017) · Nature Communications · doi:10.1038/ncomms15503 · Cited by 149
Jurmeister, P. S., Bockmayr, M. L., Seegerer, P., Bockmayr, T., Treue, D., Montavon, G., Vollbrecht, C., Arnold, A., Teichmann, D., Bressem, K. K., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aaw8513 · Cited by 174
Using high-density DNA methylation arrays to profile copy number alterations
Feber, A., Guilhamon, P., Lechner, M., Fenton, T., Wilson, G. A., Thirlwell, C., Morris, T. J., Flanagan, A. M., Teschendorff, A. E., Kelly, J. D., et al. (2014) · Genome Biology · doi:10.1186/gb-2014-15-2-r30 · Cited by 149
Paik, P. K., Shen, R., Berger, M. F., Ferry, D. R., Soria, J., Mathewson, A. M., Rooney, C., Smith, N. R., Cullberg, M., Kilgour, E., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0645 · Cited by 162
Sivakumar, S., Moore, J. A., Montesion, M., Sharaf, R., Lin, D. I., Colón, C. I., Fleischmann, Z., Ebot, E. M., Newberg, J. Y., Mills, J. M., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0620 · Cited by 175
Paik, P. K., Shen, R., Won, H., Rekhtman, N., Wang, L., Sima, C. S., Arora, A., Seshan, V., Ladanyi, M., Berger, M. F., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-1129 · Cited by 147
Chen, X.-X., Zhong, Q., Liu, Y., Yan, S.-M., Chen, Z.-H., Jin, S., Xia, T., Li, R., Zhou, A.-J., Su, Z., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00650-0 · Cited by 154
Palakurthi, S., Kuraguchi, M., Zacharek, S. J., Zudaire, E., Huang, W., Bonal, D. M., Liu, J., Dhaneshwar, A., DePeaux, K., Gowaski, M. R., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0595 · Cited by 147
The importance of p53 pathway genetics in inherited and somatic cancer genomes
Stracquadanio, G., Wang, X., Wallace, M. D., Grawenda, A. M., Zhang, P., Hewitt, J., Zerón-Medina-Cuairán, J., Castro-Giner, F., Tomlinson, I. P. M., Goding, C. R., et al. (2016) · Nature reviews. Cancer · doi:10.1038/nrc.2016.15 · Cited by 150
Mateo, J., Ganji, G., Lemech, C., Burris, H. A., Han, S.-W., Swales, K., Decordova, S., DeYoung, M. P., Smith, D. A., Kalyana-Sundaram, S., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0725 · Cited by 145
Lung Cancer Biomarkers: Present Status and Future Developments
Cagle, P. T., Allen, T. C., & Olsen, R. J. (2013) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2013-0319-cr · Cited by 164
Lee, Y. J., Shin, K. J., Park, S.-A., Park, K. S., Park, S., Heo, K., Seo, Y.-K., Noh, D.-Y., Ryu, S. H., & Suh, P.-G. (2016) · Oncotarget · doi:10.18632/oncotarget.12286 · Cited by 144
Imaging Heterogeneity in Lung Cancer: Techniques, Applications, and Challenges
Bashir, U., Siddique, M. M., McLean, E., Goh, V., & Cook, G. (2016) · American Journal of Roentgenology · doi:10.2214/ajr.15.15864 · Cited by 148
Almodovar, K., Iams, W. T., Meador, C. B., Zhao, Z., York, S. J., Horn, L., Yan, Y., Hernandez, J., Chen, H., Shyr, Y., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.09.1951 · Cited by 150
Dietel, M., Jöhrens, K., von Laffert, M., Hummel, M., Bläker, H., Pfitzner, B. M., Lehmann, A., Denkert, C., Darb‐Esfahani, S., Lenze, D., et al. (2015) · Cancer Gene Therapy · doi:10.1038/cgt.2015.39 · Cited by 167
Multiplatform-based molecular subtypes of non-small-cell lung cancer
Chen, F., Zhang, Y., Parra, E. R., Rodriguez‐Canales, J., Behrens, C., Akbani, R., Lu, Y., Kurie, J. M., Gibbons, D. L., Mills, G. B., et al. (2016) · Oncogene · doi:10.1038/onc.2016.303 · Cited by 160
Molecular targeted therapy in the treatment of advanced stage non‐small cell lung cancer ( NSCLC )
Kumarakulasinghe, N. B., van Zanwijk, N., & Soo, R. A. (2015) · Respirology · doi:10.1111/resp.12490 · Cited by 155
The National Lung Matrix Trial of personalized therapy in lung cancer
Middleton, G., Fletcher, P., Popat, S., Savage, J., Summers, Y., Greystoke, A., Gilligan, D., Cave, J., O’Rourke, N., Brewster, A., et al. (2020) · Nature · doi:10.1038/s41586-020-2481-8 · Cited by 140
FGFR3-TACC3 fusion in solid tumors: mini review
Costa, R. L. B., Carneiro, B. A., Taxter, T., Tavora, F. A., Kalyan, A., Pai, S. G., Chae, Y. K., & Giles, F. J. (2016) · Oncotarget · doi:10.18632/oncotarget.10482 · Cited by 142
Molecularly Targeted Therapies in Non–Small-Cell Lung Cancer Annual Update 2014
Morgensztern, D., Campo, M. J., Dahlberg, S. E., Doebele, R. C., Garon, E. B., Gerber, D. E., Goldberg, S. B., Hammerman, P. S., Heist, R. S., Hensing, T. A., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000405 · Cited by 150
Cancer-Derived Mutations in KEAP1 Impair NRF2 Degradation but not Ubiquitination
Hast, B. E., Cloer, E. W., Goldfarb, D., Li, H., Siesser, P. F., Yan, F., Walter, V., Zheng, N., Hayes, D. N., & Major, M. B. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-1655 · Cited by 138
Self-citationSPAG6 and L1TD1 are transcriptionally regulated by DNA methylation in non-small cell lung cancers
Altenberger, C., Heller, G., Ziegler, B., Tomasich, E., Marhold, M., Topakian, T., Müllauer, L., Heffeter, P., Láng, G., End‐Pfützenreuter, A., et al. (2017) · Molecular Cancer · doi:10.1186/s12943-016-0568-5 · Cited by 152
Genomic landscape associated with potential response to anti-CTLA-4 treatment in cancers
Ock, C.-Y., Hwang, J.-E., Keam, B., Kim, S.-B., Shim, J.-J., Jang, H.-J., Park, S., Sohn, B. H., Cha, M., Ajani, J. A., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01018-0 · Cited by 138
Orvis, T., Hepperla, A., Walter, V., Song, S., Simon, J., Parker, J., Wilkerson, M. D., Desai, N., Major, M. B., Hayes, D. N., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0061 · Cited by 137
Amin, A. R. M. R., Karpowicz, P. A., Carey, T. E., Arbiser, J. L., Nahta, R., Chen, Z. G., Dong, J., Küçük, Ö., Khan, G. N., Huang, G. S., et al. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.02.005 · Cited by 166
Genomic Profiling of Penile Squamous Cell Carcinoma Reveals New Opportunities for Targeted Therapy
McDaniel, A. S., Hovelson, D. H., Cani, A. K., Liu, C., Zhai, Y., Zhang, Y., Weizer, A. Z., Mehra, R., Feng, F. Y.-C., Alva, A. S., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-1004 · Cited by 137
Tao, S., Rojo de la Vega, M., Chapman, E., Ooi, A., & Zhang, D. D. (2018) · Molecular Carcinogenesis · doi:10.1002/mc.22745 · Cited by 135
The PTEN/NRF2 Axis Promotes Human Carcinogenesis
Rojo, A. I., Rada, P., Mendiola, M., Ortega-Molina, A., Wojdyla, K., Rogowska-Wrzesinska, A., Hardisson, D., Serrano, M., & Cuadrado, A. (2014) · Antioxidants & Redox Signaling · doi:10.1089/ars.2014.5843 · Cited by 135
Identification of Druggable Cancer Driver Genes Amplified across TCGA Datasets
Chen, Y., McGee, J., Chen, X., Doman, T. N., Gong, X., Zhang, Y., Hamm, N., Ma, X., Higgs, R. E., Bhagwat, S. V., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0098293 · Cited by 133
Inactivating CUX1 mutations promote tumorigenesis
Chronic Myeloid Disorders Working Group of the International Cancer Genome Consortium, Wong, C. C., Martincorena, I., Rust, A. G., Rashid, M., Alifrangis, C., Alexandrov, L. B., Tiffen, J. C., Kober, C., Green, A. R., et al. (2014) · Nature Genetics · doi:10.1038/ng.2846 · Cited by 135
Dysregulation of mitochondrial dynamics proteins are a targetable feature of human tumors
Anderson, G. R., Wardell, S. E., Çakır, M., Yip, C., Ahn, Y.-R., Ali, M., Yllanes, A. P., Chao, C., McDonnell, D. P., & Wood, K. C. (2018) · Nature Communications · doi:10.1038/s41467-018-04033-x · Cited by 146
Zheng, X., Zhang, N., Wu, H.-J., & Wu, H. (2017) · Genome Biology · doi:10.1186/s13059-016-1143-5 · Cited by 134
The lysine‐specific methyltransferase KMT2C/MLL3 regulates DNA repair components in cancer
Rampias, T. N., Karagiannis, D., Avgeris, M., Polyzos, A., Kokkalis, A., Kanaki, Z., Kousidou, E., Tzetis, M., Kanavakis, E., STRAVODIMOS, K. G., et al. (2019) · EMBO Reports · doi:10.15252/embr.201846821 · Cited by 154
A Pan-Cancer Catalogue of Cancer Driver Protein Interaction Interfaces
Porta-Pardo, E., Garcia-Alonso, L., Hrabe, T., Dopazo, J., & Godzik, A. (2015) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1004518 · Cited by 133
Cross-cancer profiling of molecular alterations within the human autophagy interaction network
Lebovitz, C. B., Robertson, A. G., Goya, R., Jones, S. J., Morin, R. D., Marra, M. A., & Gorski, S. M. (2015) · Autophagy · doi:10.1080/15548627.2015.1067362 · Cited by 132
Metadata
- Authors
- The Cancer Genome Atlas Research Network
- Venue
- Nature
- Published
- 2012-09-09
- Volume
- 489
- Issue
- 7417
- Pages
- 519-525
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC3466113
- OpenAlex
- W2275877493
- Cited by
- 3,994
- References
- 45
- Citations by year
- 2026: 153 · 2025: 181 · 2024: 189 · 2023: 204 · 2022: 262 · 2021: 296 · 2020: 360 · 2019: 286 · 2018: 329 · 2017: 353 · 2016: 346 · 2015: 371 · 2014: 335 · 2013: 300 · 2012: 24
- FWCI
- 263.50
- Type
- journal article
- Language
- en
- Update notices
- erratum (2012-11-07)
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-sa
- creativecommons.org/licenses/by-nc-sa/3.0/ (tdm)
- creativecommons.org/licenses/by-nc-sa/3.0/ (vor)
- Locations
- Nature (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Kölner Universitäts PublikationsServer (Universität zu Köln) (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by-nc-sa)
- DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by-nc-sa)
- Max Planck Institute for Plasma Physics (submittedVersion)
- eSpace (Curtin University) (submittedVersion, cc-by-nc-sa)
- MPG.PuRe (Max Planck Society) (submittedVersion)
- Scholarworks@UNIST (Ulsan National Institute of Science and Technology) (submittedVersion)
- Funders
- National Institutes of Health (5r01ca149569-05)
- BC Cancer Agency
- National Human Genome Research Institute (U54HG003067, HG003067, U54HG003079, HG003079, HG003273, U54HG003273, R01HG006272)
- National Cancer Institute (R01CA094143, U24CA126554, U24CA143882, R01-CA149569, U24CA143843, U24CA143840, U24CA126546, CA143883, U24CA143858, K08CA137153, U24CA126543, U24CA144025, U24CA126563, U24CA143866, U24CA143883, CA143840, U24CA143845, U24CA126544, R00CA149182, U24CA143867, U24CA143848, U24CA143799, U24CA126551, U24CA143835, U24CA126561, T32CA009172, P30CA016672, P30CA016086)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Keywords
- lung squamous cell carcinoma, genetic alterations, epigenomic alterations, TP53 mutation, copy number alterations, genome rearrangement, Nrf2, Keap1, PI3K signaling, CDKN2A, RB1, therapeutic target, TCGA
- MeSH terms
- Adenocarcinoma of Lung, Adenocarcinoma, Carcinoma, Squamous Cell, DNA Mutational Analysis, Humans, Lung Neoplasms, Mutation, Signal Transduction, Genome, Human, Gene Expression Regulation, Neoplastic, Genes, p53, Gene Deletion, Phosphatidylinositol 3-Kinases, Genes, p16, Gene Expression Profiling, Genomics, Molecular Targeted Therapy, Mutation Rate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.